Treatment of all forms of tuberculosis.
Improvement of severe tremor in multiple sclerosis.
Previous isoniazid-associated hepatic injury, drug fever, chills, or arthritis; acute liver disease.
Use Cautiously in:
CNS: psychosis, seizures .
EENT: visual disturbances .
GI: drug-induced hepatitis , nausea, vomiting.
Endo: gynecomastia .
Hemat: blood dyscrasias.
Neuro: peripheral neuropathy.
May reduce oral absorption of isoniazid; give isoniazid 1 to 3 h before aluminum salts.
May result in carbamazepine toxicity or isoniazid hepatotoxicity. Monitor carbamazepine concentrations and liver function.
May result in increased incidence of CNS effects (eg, coordination difficulties, confusion, irritability, aggressiveness).
May result in high-output renal failure in rapid acetylators. Monitor renal function.
May increase serum hydantoin levels.
May result in higher rate of hepatotoxicity.
Therapeutic Classification: antituberculars
Absorption: Well absorbed following PO/IM administration.
Distribution: Widely distributed; readily crosses the blood-brain barrier. Crosses the placenta; enters breast milk in concentrations equal to plasma.
Metabolism/Excretion: 50% metabolized by the liver at rates that vary widely among individuals; 50% excreted unchanged by the kidneys.
Half-life: 1–4 hr.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal